Study offers possible treatment for frontotemporal dementia
Drug Discovery World
SEPTEMBER 9, 2024
Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)). Frontotemporal dementia is the most common cause of dementia in people under the age of 60.
Let's personalize your content